Name: Latest research reports of Biocon Ltd. authored by ICICI Securities Limited and published by - Trendlyne research reports.
Item: Biocon Ltd.
Rating: 3
Author: ICICI Securities Limited

Biocon Ltd.

NSE: BIOCON | BSE: 532523 | ISIN: INE376G01013 | Industry: Biotechnology
| Strong Performer, Getting Expensive

396.8500 1.70 (0.43%)

NSE Nov 21, 2025 15:31 PM

New 52W High in past week

Volume: 3.3M

Biocon Ltd.

04 Mar 2022

396.85

0.43%

Biocon

Hold: Biocon Ltd.

Target

ICICI Securities Limited

Biosimilar US pipeline: (approvals - Pegfilgrastim, Trastuzumab, Glargine, Adalimumab); filed - Aspart and Bevacizumab Revenue breakup FY21: biosimilars (37%), generics (31%), CRAMS (29%)...

ICICI Securities Limited increased Sell price target of Biocon Ltd. to 320.0 on 14 Nov, 2025.